SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-031373
Filing Date
2022-03-08
Accepted
2022-03-08 11:45:42
Documents
12
Period of Report
2022-03-08
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm228420d4_8k.htm   iXBRL 8-K 26562
  Complete submission text file 0001104659-22-031373.txt   201972

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vyne-20220308.xsd EX-101.SCH 3060
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE vyne-20220308_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vyne-20220308_pre.xml EX-101.PRE 22613
6 EXTRACTED XBRL INSTANCE DOCUMENT tm228420d4_8k_htm.xml XML 3708
Mailing Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807
Business Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

IRS No.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38356 | Film No.: 22720842
SIC: 2834 Pharmaceutical Preparations